BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Clinical trial NCT06787989 · RECRUITING

Trial details

NCT number: NCT06787989
Sponsor: iCell Gene Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Immune Cytopenia

Start date: 2024-08-31
Primary completion: 2026-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.